Dimensional Fund Advisors LP Acquires 231,034 Shares of Annexon, Inc. (NASDAQ:ANNX)

Dimensional Fund Advisors LP lifted its position in Annexon, Inc. (NASDAQ:ANNX - Free Report) by 20.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,360,076 shares of the company's stock after acquiring an additional 231,034 shares during the quarter. Dimensional Fund Advisors LP owned 1.28% of Annexon worth $6,977,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in ANNX. Vanguard Group Inc. raised its position in Annexon by 11.6% in the 4th quarter. Vanguard Group Inc. now owns 5,546,918 shares of the company's stock worth $28,456,000 after purchasing an additional 576,625 shares during the period. Mutual of America Capital Management LLC grew its stake in shares of Annexon by 56.2% during the fourth quarter. Mutual of America Capital Management LLC now owns 1,029,680 shares of the company's stock valued at $5,282,000 after buying an additional 370,426 shares during the last quarter. Candriam S.C.A. lifted its stake in shares of Annexon by 15.6% during the 4th quarter. Candriam S.C.A. now owns 2,534,230 shares of the company's stock worth $13,001,000 after acquiring an additional 341,431 shares during the last quarter. Walleye Capital LLC lifted its stake in shares of Annexon by 99.7% during the 4th quarter. Walleye Capital LLC now owns 656,332 shares of the company's stock worth $3,367,000 after acquiring an additional 327,634 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in Annexon by 16.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,706,182 shares of the company's stock valued at $10,101,000 after acquiring an additional 235,810 shares during the period.

Annexon Stock Up 3.0%

NASDAQ:ANNX traded up $0.06 during midday trading on Friday, hitting $1.87. The stock had a trading volume of 253,450 shares, compared to its average volume of 1,584,212. The stock has a 50-day moving average of $1.92 and a 200 day moving average of $3.72. The company has a market capitalization of $204.62 million, a price-to-earnings ratio of -1.78 and a beta of 1.24. Annexon, Inc. has a one year low of $1.28 and a one year high of $7.85.

Annexon (NASDAQ:ANNX - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.07). On average, sell-side analysts anticipate that Annexon, Inc. will post -0.96 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Needham & Company LLC decreased their target price on Annexon from $16.00 to $11.00 and set a "buy" rating for the company in a research report on Tuesday. HC Wainwright reduced their price target on shares of Annexon from $20.00 to $14.00 and set a "buy" rating on the stock in a research note on Wednesday.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.